Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > 'Won't find a more full pipeline for a company this size'
View:
Post by prophetoffactz on Dec 20, 2022 9:25am

'Won't find a more full pipeline for a company this size'

Some very rough notes from presentation this morning...

Midatech was hoping for catalysts to do a financing:

Progression free surivivl trial but was delayed by regulators
Q-Sphera deal. couldn't get it over the line. big pharma march to own drummer

Hit:

worst financial market
tourist investors moved on to other sectors.
many biotechs trading below cash

financing extremely difficult.

went with BTI as best option

robust very valuble assets
6 products 6 indications
as platforms brought to proof of concept have a pipeline opportunity

multi-asset news flow

first patient glioblastoma was positive and patient recovering. 
phase II could be enough for other indicatin one patient more to recruit in phase I

merged company won't find a more full pipeline for a company this size.

triial rare and orphan strategy regulators offer shortcuts and exclusivity

five platforms

100,000 X drug in the tumor
in screen of 83 drugs one of most effective. 
DIPG median survival 26 months vs. 10 months. Surprisingly strong result

stat sig in mice
compelling results in human cell lines.
Comment by emmitfitzhume on Dec 20, 2022 9:35am
"...after completion of the murder, I mean merger...."  Dr. Deborah Rathjen. Freudian slip?  Sure does feel like current shareholders are getting murdered....
Comment by zwerp2000 on Dec 20, 2022 10:04am
Absolutely absurd. Stop trying to fool everyone with your irresponsible posts. The stock is $.03 US right now, Shareholders were burned bigtime by management. Game over. Move on. Nothing you've said over the years has remotely come true
Comment by prophetoffactz on Dec 20, 2022 10:38am
Q-Sphera deal. couldn't get it over the line. big pharma march to own drummer One can imagine big pharma negotiating a deal and seeing Midatech almost out of cash and desperate in the worst biotech financing market imaginable. They drag their feet waiting for Midatech to capitulate.  With the cash from the financing Midatech will be in a stronger position. More than one company is ...more  
Comment by prophetoffactz on Dec 20, 2022 12:16pm
Rathjen and Saltarelli are on the Advisory Board with Chiesi overseeing Chiesi's xB3-LSD programs. The impression we are left with is that work continues. That BTI nominated Hunter as its lead xB3 asset, that Biodexa will also have Hunter as its lead xB3 program, and that Mario Salterelli is continuing and excited about the future of Biodexa would appear to argue for Chiesi's continued ...more  
Comment by prophetoffactz on Dec 20, 2022 12:32pm
There is the US$10 million upfront from the financing and a potential second US$10 million upon exercise of warrants that could be triggered in 2023 given the expected event horizon. Add payments from potential deals for xB3 and Q-Sphera and that can further support the cash runway through hard data catalysts. Midatech's CEO is hopeful for a deal with J&J on Q-Sphera in 2023. BTI's xB3 ...more  
Comment by prophetoffactz on Dec 20, 2022 6:01pm
With Chiesi now 2 1/2 years into its xB3 deal, Biodexa nominating Hunter as its lead xB3 asset with preclinical data expected in Q2, and Chiesi's potential FDA approval for its strategic Fabry asset in the first half of 2023 from both the FDA and European authorities, will Chiesi file for approval to commence an xB3 trial in 2023? Lysosomal Storage Disorders is a strategic area for Chiesi and ...more  
Comment by prophetoffactz on Dec 20, 2022 6:43pm
Biodexa will have a much stronger profile and much more credibility to pursue xB3 and Q-Sphera partnerships. I think this deal will accelerate xB3 and Q-Sphera. Being out of money, in debt, with a $10 million market cap trading on the TSX-V by appointment could be a big turn-off for many companies doing their DD on BTI. How stable is it? Biodexa's much stronger profile, asset base, and the ...more  
Comment by unclepieman on Dec 20, 2022 12:52pm
stop the pump, no one cares anymore
Comment by fuzzyjr on Dec 20, 2022 1:15pm
"stop the pump, no one cares anymore" you should care , like it or not this is a new beginning & the future of this company- something much bigger imo.A tiny piece of a good pie is better than the slop we had.Stop the bashing now - has it ever did a lick a good, obviously not.   Have a buddy who just got in buying 250k shares & he is pumped about the future - depends ...more  
Comment by unclepieman on Dec 20, 2022 4:15pm
No, actually I don't care.  On my way out and I'll be burning this MF house down with my $. Enjoy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities